{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:19:15Z","timestamp":1788898755067,"version":"build-2803163510"},"reference-count":63,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Previous analyses of pooled DISCOVER\u20101 and DISCOVER\u20102 data through Week 24 showed significantly higher rates of dactylitis resolution in patients treated with guselkumab compared with placebo. Here, we investigate associations between dactylitis resolution and other outcomes through 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients were randomized 1:1:1 to receive subcutaneous injections of guselkumab 100 mg at Week 0, Week 4, and then every 4 or 8\u2009weeks, or placebo with crossover to guselkumab at Week 24. Independent assessors determined dactylitis severity score (DSS; 0\u20103\/digit; total\u00a0=\u00a00\u201060). Dactylitis resolution (DSS\u00a0=\u00a00) (prespecified) and at least 20%, at least 50%, and at least 70% DSS improvement from baseline (post hoc) were determined through Week 52 (nonresponder imputation for treatment failure through Week 24 and for missing data through Week 52). ACR50, tender\/swollen joints, low disease activity (LDA) as assessed by composite indices, and radiographic progression (DISCOVER\u20102 only) were assessed in patients with dactylitis versus without dactylitis resolution at Week 24 and Week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with dactylitis at baseline (473 of 1118) had more severe joint and skin disease than those without dactylitis (645 of 1118). At Week 52, approximately 75% of guselkumab\u2010randomized patients with dactylitis at baseline had complete resolution; approximately 80% had at\u00a0least\u00a070% DSS improvement. Through Week 52, new\u2010onset dactylitis (DSS \u22651) was uncommon among patients with a DSS of 0 at baseline. Guselkumab\u2010randomized patients with dactylitis resolution were more likely to achieve ACR50, at\u00a0least\u00a050% reduction in tender and swollen joints, and LDA at Week 24 and Week 52 than those without resolution. At Week 52, patients with dactylitis resolution had numerically less radiographic progression from baseline (DISCOVER\u20102).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Through 1 year, approximately 75% of guselkumab\u2010randomized patients had complete resolution of dactylitis; patients exhibiting resolution were more likely to achieve other important clinical outcomes. Given the high burden of dactylitis, resolution may be associated with better long\u2010term patient outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11537","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T09:55:00Z","timestamp":1678182900000},"page":"227-240","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Guselkumab, a Selective Interleukin\u201023 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies"],"prefix":"10.1002","volume":"5","author":[{"given":"Dennis","family":"McGonagle","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) University of Leeds; National Institute for Health Research (NIHR) Biomedical Research Centre  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation University of Glasgow  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University  Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg  Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson &amp; Johnson  Horsham Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, and Drexel University College of Medicine  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie L.","family":"Xu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Sheng","sequence":"additional","affiliation":[{"name":"Immunology Biostatistics, Janssen Research &amp; Development, LLC  Spring House Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Xu","sequence":"additional","affiliation":[{"name":"Immunology Biostatistics, Janssen Research &amp; Development, LLC  Spring House Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center  Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[{"name":"Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland  St John's Newfoundland Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Phillip J.","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center\/Providence St. Joseph Health and University of Washington School of Medicine  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130163"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S60821"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220964"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0147-9"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04683-2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez549"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018184"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150165"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23249"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0029-z"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0377-2"},{"issue":"10","key":"e_1_2_8_15_1","first-page":"S688","article-title":"Long term improvements in physical function are associated with improvements in dactylitis, enthesitis, tender and swollen joint counts, and psoriasis skin involvement: results from a phase 3 study of ustekinumab in psoriatic arthritis patients","volume":"66","author":"Kavanaugh A","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1831-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001217"},{"key":"e_1_2_8_18_1","volume-title":"TREMFYA\u00ae (guselkumab) injection, for subcutaneous use","year":"2020"},{"key":"e_1_2_8_19_1","first-page":"114","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic\u2010naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER\u20101): a double\u2010blind, randomised, placebo\u2010controlled phase 3 trial. Lancet 2020;395:1115\u201325","volume":"395","author":"Deodhar A","year":"2020","journal-title":"Erratum in: Lancet"},{"key":"e_1_2_8_20_1","first-page":"1114","article-title":"Guselkumab in biologic\u2010naive patients with active psoriatic arthritis (DISCOVER\u20102): a double\u2010blind, randomised, placebo\u2010controlled phase 3 trial. Lancet 2020;395:1126\u201336","volume":"395","author":"Mease PJ","year":"2020","journal-title":"Erratum in: Lancet"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41553"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42010"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216500"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"e_1_2_8_30_1","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella D","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_8_32_1","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64","author":"Heijde D","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140172"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00206-1"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325967116674714"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180971"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220098"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3304-z"},{"key":"e_1_2_8_44_1","first-page":"1677","article-title":"Articular and extra\u2010articular benefits in ACR20 non\u2010responders at Week 104 treated with apremilast: pooled analysis of three randomized controlled trials","volume":"8","author":"Mease PJ","year":"2021","journal-title":"Rheumatol Ther"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.02.002"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000155"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65269-6"},{"issue":"93","key":"e_1_2_8_48_1","first-page":"S20","article-title":"The joint in psoriatic arthritis","volume":"33","author":"Mortezavi M","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217372"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180797"},{"key":"e_1_2_8_57_1","first-page":"508","article-title":"Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta\u2010analysis on articular, enthesitis, dactylitis, skin and functional outcomes","volume":"38","author":"Simons N","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001486"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190507"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.05.004"},{"key":"e_1_2_8_61_1","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell PS","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_62_1","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: which is the best instrument to use?","volume":"34","author":"Healy PJ","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_63_1","first-page":"1740","article-title":"International spondyloarthritis interobserver reliability exercise\u2010\u2010the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis","volume":"34","author":"Gladman DD","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1168-6636"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11537","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11537","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:55:56Z","timestamp":1759424156000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1002\/acr2.11537"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11537","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"2022-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}